Cell MedX Corp Stock OTC Bulletin Board
Equities
US15115X1072
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-15 | Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
03-12 | Cell MedX Corp. announced that it has received $0.075 million in funding | CI |
Sales 2022 | 0.01 0.01 | Sales 2023 | 0 0 | Capitalization | 6.29K 8.6K |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1,135,153,669 x |
Net Debt 2022 | 592K 810K | Net Debt 2023 | 903K 1.23M | EV / Sales 2023 | 329,116,944 x |
P/E ratio 2022 |
-9.01
x | P/E ratio 2023 |
-0.01
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.34% |
Managers | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Yanika Silina
DFI | Director of Finance/CFO | 46 | 14-11-23 |
George Adams
CHM | Chairman | 76 | 18-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Dwayne Yaretz
BRD | Director/Board Member | 63 | 22-04-26 |
Joao da Costa
BRD | Director/Board Member | 59 | 20-06-07 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |